Journal Article

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Lee, Min-Jung, Lee, Jung-Min, Lee, Sunmin, Atkins, Sarah L P, Rastogi, Shraddha, Annunziata, Christina M, Sato, Nahoko, Gatti-Mays, Margaret E, Zimmer, Alexandra S, Burks, Christina, Lipkowitz, Stanley, Jenkins, Sarah, Houston, Nicole, Trepel, Jane B, Greer, Yoshimi Endo, Nagashima, Kunio

2023

Overview

Abstract Background ONC201 is a small molecule that can cause nonapoptotic cell death through loss of mitochondrial function. Results from the phase I/II trials of ONC201 in patients with refractory solid tumors demonstrated tumor responses and prolonged stable disease in some patients. Methods This single-arm, open-label, phase II clinical trial evaluated the efficacy of ONC201 at the recommended phase II dose (RP2D) in patients with recurrent or refractory metastatic breast or endometrial cancer. Fresh tissue biopsies and blood were collected at baseline and at cycle 2 day 2 for correlative studies. Results Twenty-two patients were enrolled; 10 patients with endometrial cancer, 7 patients with hormone receptor–positive breast cancer, and 5 patients with triple-negative breast cancer. The overall response rate was 0%, and the clinical benefit rate, defined by complete response (CR) + partial response (PR) + stable disease (SD), was 27% (n = 3/11). All patients experienced an adverse event (AE), which was primarily low grade. Grade 3 AEs occurred in 4 patients; no grade 4 AEs occurred. Tumor biopsies did not show that ONC201 consistently induced mitochondrial damage or alterations in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the TRAIL death receptors. ONC201 treatment caused alterations in peripheral immune cell subsets. Conclusion ONC201 monotherapy did not induce objective responses in recurrent or refractory metastatic breast or endometrial cancer at the RP2D dose of 625 mg weekly but had an acceptable safety profile (ClinicalTrials.gov Identifier: NCT03394027). This phase II clinical trial evaluated ONC201 monotherapy, using the previously established recommended phase II dose, in patients with recurrent or refractory metastatic breast or endometrial cancer.

• Publisher: Oxford University Press
• Subject: Antimitotic agents / Antineoplastic agents / Antineoplastic Agents - adverse effects / Biopsy / Breast cancer / Cancer / Care and treatment / Cell death / Clinical Trial Results / Clinical trials / Diagnosis / Dosage and administration / Endometrial cancer / Endometrial Neoplasms - drug therapy / Female / Health aspects / Humans / Metastasis / Neoplasm Recurrence, Local - drug therapy / Oncology, Experimental / Risk factors / Triple Negative Breast Neoplasms - drug therapy / Triple Negative Breast Neoplasms - pathology